Web focuses

A Web Focus is a collection of articles on a related theme. With content ranging from Research Highlights through to Reviews and Perspectives, a Web Focus provides a panoramic view of a key area of drug discovery and development.




2015


Collections

Cancer immunotherapy

September

Produced with support of a grant from Bristol-Myers Squibb

Cancer immunotherapy, which encompasses a variety of approaches that mobilise the immune system to seek out and kill cancer cells, is showing substantial potential to transform the treatment of cancer. Articles in this collection highlight the progress being made with several of the most promising immunotherapy approaches and discuss key issues for maximizing their benefits, such as how immunotherapies may be rationally combined with each other or with traditional anticancer drugs.
All content for this collection has been chosen by the editors of Nature Reviews Drug Discovery and has been made freely available for 6 months, thanks to support of a grant from Bristol-Myers Squibb.


2014


Focus

US drug development consortia

November

Launched a decade ago, the US Food and Drug Administration's Critical Path Initiative has helped catalyse the formation of many consortia focused on drug development challenges. In this Focus, representatives from some of the major stakeholder groups and consortia describe their roles, summarize progress so far and provide their perspectives on the opportunities, challenges and lessons learned for biomedical consortia in general.


2012


Collections

Ten years in drug discovery

January

To mark the tenth anniversary of Nature Reviews Drug Discovery, this collection brings together data on key indicators for the field over the past decade, as well as a selection of some of the most highly cited and downloaded articles published in the journal from each of the last ten years.



2011


Collections

Rare Diseases

September

Produced with support from Shire

Many of the thousands of rare diseases lack effective treatments. However, economic and regulatory incentives, as well as advances in our understanding of disease aetiology, have encouraged increased investment in the development of drugs for rare diseases — orphan drugs. This special collection from Nature Reviews Drug Discovery includes articles that discuss the impact of orphan drug legislation in the United States and Europe, and that review recent therapeutic progress for two groups of rare diseases: neuromuscular disorders and myeloproliferative neoplasias.


2010


Collections

Type 2 Diabetes

June

Produced with support from Roche

The rapid growth in the prevalence of type 2 diabetes is increasing the need for effective therapeutic interventions. However, although multiple classes of diabetes drugs are available, achieving long-term control of blood sugar is often a major challenge, in part owing to treatment-limiting adverse effects. With these challenges in mind, this special collection of articles from Nature Reviews Drug Discovery focuses on emerging therapeutic approaches and targets for type 2 diabetes.


2008

Focus

Apoptosis

December

Supported by Genentech, Inc.

Apoptosis, the major form of controlled cell death, has a key role in the pathogenesis of diseases including cancer, inflammation and neurodegenerative disorders. The past decade has witnessed tremendous progress in understanding of the molecular mechanisms of apoptosis regulation, which has revealed a number of highly promising therapeutic targets, particularly for anticancer strategies. This focus provides a cutting-edge overview of the science and business of targeting apoptosis.


Focus

Pain

August

Produced with support from Eli Lilly and Company, which had no control over its content.

Unrelieved pain associated with conditions such as arthritis, diabetes, cancer and serious injury represents a major unmet medical need. With the aim of highlighting approaches to tackling the challenges in this field, this special collection integrates articles that discuss strategies to drive forward analgesic drug development with those that explore new targets for pain therapeutics.


2007

Focus

Antivirals

December

Produced with support from Pfizer (principal sponsor) and Gilead (supporting sponsor)

The emergence of new viral pathogens, the increasing prevalence of chronic viral diseases and the risk of drug resistant viral strains has increased demand for new antiviral strategies. This joint focus with Nature Biotechnology provides an update on the science and business of antiviral R&D, highlighting innovative approaches and lessons learned from three decades of antiviral drug development.


2006

Focus

Antibacterials

December

Produced with support from AstraZeneca and Wyeth Pharmaceuticals

This focus was produced in conjunction with Nature Biotechnology and includes a collection of reviews, research highlights, news and views and commentaries covering the science and business of antibacterial drug R&D.


Focus

The molecular pharmacopoeia

December

Produced with support from Pfizer and Inpharmatica

For the past decade, the number of molecular targets for approved drugs has been debated. However, to develop and apply predictive methods to assess the future potential for therapeutic exploitation, the number, characteristics and biological diversity of these targets needs to be established. Here, we provide a comprehensive survey of current drug targets and drugs that modulate them.

2004

Focus

Atherothrombosis

January

Atherothrombosis, the leading cause of morbidity and mortality. As discussed in these articles, recent progress in the understanding of the pathogenesis of atherothrombosis, and in the application of approaches to assess disease progression, has provided new impetus to the discovery and development of novel drugs for this condition.


Focus

Proteomics

March

The collection includes forward-looking perspectives, recent research highlights and an overarching reviews article that gives an insight into the part proteomics is playing in industrial research, starting at the genome and ending with new therapeutic targets for disease.


Focus

Kinases in cancer

We examine the role of kinase signalling in cancer and the potential for developing effective therapies that can modulate various kinase pathways. Following the success of targeted kinase inhibitor therapies such as imatinib and gefitinib this continues to be a fast moving area of research.


Focus

PharmacogeneticsUpdated

January

This Focus provides a comprehensive collection of articles on the development of pharmacogenetics, covering topics ranging from the latest approaches in pharmacogenetics research to evolving regulatory frameworks and ethical issues


Top